Who are Bus and Dex's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cyclophosphamide and glucocorticoids, Cyclophosphamide and steroids, Dexamethasone, Rituximab, Cyclophosphamide, Melphalan+Prednisolone, Bortezomib, Melphalan, Prednisone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bus-and-dex.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Bus and Dex — Competitive Intelligence Brief

Bus and Dex (Bus and Dex) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alkylating agent + corticosteroid combination. Area: Oncology / Hematology.

marketed Alkylating agent + corticosteroid combination Oncology / Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Bus and Dex (Bus and Dex) — The Cleveland Clinic. Bus and Dex is a combination of busulfan and dexamethasone used to condition patients prior to hematopoietic stem cell transplantation.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Bus and Dex TARGET	Bus and Dex	The Cleveland Clinic	marketed	Alkylating agent + corticosteroid combination
Cyclophosphamide and glucocorticoids	Cyclophosphamide and glucocorticoids	Peking Union Medical College Hospital	marketed	Alkylating agent + corticosteroid combination
Cyclophosphamide and steroids	Cyclophosphamide and steroids	Radboud University Medical Center	phase 3	Alkylating agent + corticosteroid combination
Dexamethasone, Rituximab, Cyclophosphamide	Dexamethasone, Rituximab, Cyclophosphamide	University of Ulm	phase 3	Monoclonal antibody + alkylating agent + corticosteroid combination	CD20 (rituximab); DNA (cyclophosphamide); glucocorticoid receptor (dexamethasone)
Melphalan+Prednisolone	Melphalan+Prednisolone	Cigdem Sahinbas YILMAZ	phase 3	Alkylating agent + Corticosteroid combination	DNA (melphalan); glucocorticoid receptor (prednisolone)
Bortezomib, Melphalan, Prednisone	Bortezomib, Melphalan, Prednisone	Fondazione EMN Italy Onlus	phase 3	Proteasome inhibitor + alkylating agent + corticosteroid combination	20S proteasome (bortezomib); DNA (melphalan); glucocorticoid receptor (prednisone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alkylating agent + corticosteroid combination class)

Peking Union Medical College Hospital · 1 drug in this class
Radboud University Medical Center · 1 drug in this class
The Cleveland Clinic · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bus and Dex — Competitive Intelligence Brief. https://druglandscape.com/ci/bus-and-dex. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab